Innovative drug sector's stimulant! Fuguo Bank bets on Arcellx (ACLX.US) to reshape the landscape of myeloma treatment, predicting that the stock price will rise by over 50%.

According to the Securities Times app, the Wall Street financial giant Fuguo Bank has initiated coverage and set a target price for the American biotechnology newcomer Arcellx (ACLX.US), giving it an "overweight" rating. They stated that the experimental CAR-T therapy "anito-cel" used for multiple myeloma is the "future cornerstone" of this blood cancer management system and will completely reshape the landscape of myeloma treatment in the future.